An Explorative Pilot Study of a New Mobile Phone Application Measuring Eye Parameters of Eyes in Patients With SUD

Sponsor
Kontigo Care AB (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05737550
Collaborator
(none)
30
1
1
4
7.5

Study Details

Study Description

Brief Summary

This will be a pre-market, explorative, early feasibility, pilot, controlled clinical investigation designed to collect initial clinical data for Previct Drugs.

Condition or Disease Intervention/Treatment Phase
  • Device: Previct Drugs
N/A

Detailed Description

This second early feasibility study will give valuable information on the usability of Previct Drugs once being used in the intended population, i.e, patients with confirmed Substance Use Disorder (SUD). It will also give valuable information on the feasibility of Previct drugs function to measure pupils and eye movements in this population including evaluating the safety when using the device.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
The investigation aims to enroll up to 30 SUD subjects. As this is an early feasibility and explorative investigation, the sample size is not derived from a sample size calculation as no hypothesis is pre-defined. It is based on available subjects from the clinic.The investigation aims to enroll up to 30 SUD subjects. As this is an early feasibility and explorative investigation, the sample size is not derived from a sample size calculation as no hypothesis is pre-defined. It is based on available subjects from the clinic.
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
A Second Explorative Pilot Study Evaluating Usability and Functionality of a New Mobile Phone Application Measuring Eye Parameters of Eyes in Patients With Confirmed Substance Use Disorder (SUD)
Anticipated Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Jul 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Subjects with confirmed SUD

Evaluation of the usability of Previct Drugs when used in the intended population (patients with SUD).

Device: Previct Drugs
Previct Drugs is a new non CE-marked eHealth system intended to be used for future monitoring and treatment of patients with substance use disorder (SUD). Previct Drugs consists of an application (app) to be installed on a smartphone, a web-based careportal to be accessed from a computer by the healthcare professional for administration and access of registered data, and a database for storage, handling, and analysis of reported data. Previct Drugs is intended to be used by healthcare professionals and patients within treatment of SUD.

Outcome Measures

Primary Outcome Measures

  1. Evaluate if the user-interface of the mobile phone application Previct Drugs is suitable to be used by patients with substance use disorder. [Up to 4 weeks post baseline]

    Observation of a study subject during a test with Previct Drugs through answering a usability questionnaire consisting of 18 usability questions.

Secondary Outcome Measures

  1. Evaluate if self-administered pupillometry using a mobile phone application can be used to collect pupillograms for patients with substance use disorder. [Up to 4 weeks post baseline]

    The fraction of collected pupillometry data from the mobile phone application, which can be transformed into pre-defined key features using native pupillograms.

  2. Evaluate if self-administered pupillometry using a mobile phone application, after refining the method for establishing pupillograms and key feature extraction algorithms, can be used to collect pupillograms from patients with substance use disorder. [Up to 4 weeks post baseline]

    The fraction of collected pupillometry data from the mobile phone application, which can be transformed into pre-defined key features using refined pupillograms and and key feature extraction algorithms.

Other Outcome Measures

  1. Evaluate safety of using the mobile phone application Previct Drugs [Through study completion, an average of 4 weeks]

    The incidence and severity of adverse events associated with Previct Drugs

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Signed Informed Consent Form

  • Male and female

  • A recurrent visitor at Sprututbytesprogrammet in Uppsala defined as visited the clinic within the last three (3) months

  • SUD in accordanve with DSM-5 criteria according to investigator/designee judgement

  • Age 18 and above

  • Negative urine pregnancy test for all fertile women

  • Been informed of the nature, the scope, and the relevance of the clinical investigation

  • Voluntarily agreed on participation and has duly singed the Informed Consent Form

Exclusion Criteria:
  • Participating in another clinical investigation which may affect the study outcome according to clinical judgement

  • Pregnancy or lactating

  • Blind

  • Deaf

  • Any ECG dangerous arrythmia according to the investigator or designee judgement

  • Any disease or condition that may influence pupillary reflexes based on clinical judgement

  • Undergone eye surgery that may influence pupillary reflexes based on clinical judgement

  • Not able to read or understand the local language

  • Any planned travel or treatment which will make it impossible to participate according to the investigator or designee

  • Any other condition that as judged by the investigator may make the follow-up or investigation inappropriate

  • That according to the Declaration of Helsinki is deemed unsuitable for study enrolment

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mottagning för särskild vård, sprutbytet, Husläkarmottagning för hemlösa Uppsala Uppland Sweden 75323

Sponsors and Collaborators

  • Kontigo Care AB

Investigators

  • Study Chair: Markku Hämäläinen, PhD, Kontigo Care AB

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kontigo Care AB
ClinicalTrials.gov Identifier:
NCT05737550
Other Study ID Numbers:
  • KCClin02
First Posted:
Feb 21, 2023
Last Update Posted:
Feb 21, 2023
Last Verified:
Feb 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 21, 2023